Showing results (691-700 of 1,565) with videos related to
Sort By:
Pageof 157
Asia-Pacific Journal of Clinical Oncology|June 18, 2014
The PHLDB1 rs498872 (11q23.3) polymorphism and glioma risk: A meta-analysisXingchun Gao, Yajing Mi, Aili Yan, et al.Asia-Pacific Journal of Clinical Oncology|June 18, 2014
Medical models of teleoncology: current status and future directionsSabe SabesanAsia-Pacific Journal of Clinical Oncology|April 15, 2015
Prognostic factors and survival rate of osteosarcoma: A single-institution studyWan Ismail Faisham, Arman Zaharil Mat Saad, Laith N Alsaigh, et al.Asia-Pacific Journal of Clinical Oncology|April 14, 2015
Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: a meta-analysisLong Luo, Qian Hu, Jun-xia Jiang, et al.Asia-Pacific Journal of Clinical Oncology|April 14, 2015
The rapidly escalating cost of treating colorectal cancer in AustraliaSumitra Ananda, Suzanne Kosmider, Ben Tran, et al.Asia-Pacific Journal of Clinical Oncology|August 18, 2012
ERCC1 C19007T polymorphism and the risk and invasiveness of cervical cancer in Korean womenSeung-Su Han, Jae Weon Kim, Sang Hoon Lee, et al.Asia-Pacific Journal of Clinical Oncology|August 18, 2012
Mortality within 30 days of receiving systemic anti-cancer therapy at a regional oncology unit: what have we learned?Jaclyn Yoong, Jo-An Seah, Katherine Hamilton, et al.Asia-Pacific Journal of Clinical Oncology|August 18, 2012
Diagnosis prevention and treatment for PICC-related upper extremity deep vein thrombosis in breast cancer patientsLei Xing, Vishnu Prasad Adhikari, Hong Liu, et al.Asia-Pacific Journal of Clinical Oncology|August 18, 2012
Maximum SUV on positron emission tomography and serum CEA level as prognostic factors after curative resection for non-small cell lung cancerMasaki Tomita, Tetsuya Shimizu, Takanori Ayabe, et al.Asia-Pacific Journal of Clinical Oncology|August 18, 2012
Syndrome of inappropriate anti-diuretic hormone secretion secondary to carboplatin after docetaxel-carboplatin-trastuzumab combination for early stage HER-2 positive breast cancerNatalie Turner, Josephine Stewart, Frances Barnett, et al.Pageof 157